Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascentage Pharma Group International (AAPG) Other Non-Current Assets (2022 - 2025)

Ascentage Pharma Group International posted quarterly Other Non-Current Assets of $4.3 million for Q4 2025, up 26.32% year-on-year from $3.4 million in Q4 2024, and down 68.67% on a QoQ basis from $13.8 million in Q2 2025.

Ascentage Pharma Group International (AAPG) has 4 years of Other Non-Current Assets data on file, last reported at $4.3 million in Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Assets rose 26.32% year-over-year to $4.3 million; the trailing twelve-month figure through Dec 2025 stood at $4.3 million (up 26.32% YoY), and the FY2025 full-year result was $4.4 million, down 45.92% from the prior year.
  • Other Non-Current Assets for Q4 2025 stood at $4.3 million, down from $13.8 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $13.8 million in Q2 2025 and bottomed at $2.3 million in Q4 2022.
  • The 4-year median for Other Non-Current Assets is $3.4 million (2024), against an average of $5.5 million.
  • The widest annual swing landed in 2023, when Other Non-Current Assets soared 46.0%; it then rose 0.63% in 2024.
  • A 4-year view of Other Non-Current Assets shows it stood at $2.3 million in 2022, then jumped by 46.0% to $3.4 million in 2023, then climbed by 0.63% to $3.4 million in 2024, then increased by 26.32% to $4.3 million in 2025.
  • The last three Other Non-Current Assets figures came in at $4.3 million (Q4 2025), $13.8 million (Q2 2025), and $3.4 million (Q4 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Other Non-Current Assets (Qtr)
1 Quantum Biopharma 1,638,563.89 Bn 1,638,563.89 Bn - -
2 Alterity Therapeutics 767,934.24 Bn 767,934.20 Bn - -
3 Legend Biotech 2,937.00 Bn 2,936.10 Bn 242.10 Mn 12.40 Mn
4 Nanobiotix 2,282.79 Bn 2,282.72 Bn - -
5 Akari Therapeutics 2,169.69 Bn 2,169.69 Bn - 60,000.00
6 Vertex Pharmaceuticals 110.41 Bn 103.16 Bn 2.59 Bn 1.26 Bn
7 Regeneron Pharmaceuticals 66.44 Bn 57.69 Bn 3.31 Bn 2.13 Bn
8 Evaxion A 65.44 Bn 65.42 Bn - -
9 Alnylam Pharmaceuticals 39.53 Bn 36.52 Bn 959.66 Mn 63.55 Mn
10 Ascentage Pharma Group International 1.11 Bn 937.28 Mn - 4.33 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 4.33 Mn
Jun 30, 2025 13.83 Mn
Dec 31, 2024 3.43 Mn
Dec 31, 2023 3.41 Mn
Dec 31, 2022 2.33 Mn